Literature DB >> 24990872

Long-term outcomes of optical coherence tomography-guided transepithelial phototherapeutic keratectomy for the treatment of anterior corneal scarring.

Sloan W Rush1, Jennifer Matulich2, Ryan B Rush3.   

Abstract

AIM: To report the long-term outcomes of optical coherence tomography (OCT)-guided transepithelial phototherapeutic keratectomy (PTK) for the management of anterior corneal scarring.
METHODS: The charts of 60 patients (64 eyes) who underwent OCT-guided transepithelial PTK for anterior corneal scarring were retrospectively reviewed. The procedure involved a preoperative OCT-measured depth of treatment calculation to reduce or eliminate corneal scarring, followed by a combined myopic and hyperopic transepithelial excimer laser treatment profile established to attain the desired refractive result. The main outcome measures consisted of change in best spectacle-corrected visual acuity (BSCVA), change in OCT-measured parameters, and change in corneal topography indices.
RESULTS: The mean follow-up was 41.0 weeks (range: 12-117 weeks). BSCVA improved from a mean of 0.77 logMAR (0.65-0.89) preoperatively to a mean of 0.34 logMAR (0.21-0.46) postoperatively (p<0.0001). Comparison of preoperative and postoperative corneal topographic indices showed significant improvement in all parameters analysed: corneal cylinder (p=0.0008), surface asymmetry index (p=0.0054), surface regularity index (p=0.0047) and projected visual acuity (p=0.0045). Postoperative spherical equivalent averaged 0.91 (±0.71) dioptres of error from the intended target refractive outcome. Two patients required penetrating keratoplasty and one patient underwent repeat PTK during the study interval.
CONCLUSIONS: The OCT-guided transepithelial PTK technique described in this study can deliver positive long-term results and predictable refractive outcomes in the treatment of anterior corneal scarring. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Entities:  

Keywords:  Cornea; Imaging

Mesh:

Year:  2014        PMID: 24990872     DOI: 10.1136/bjophthalmol-2014-305366

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  6 in total

Review 1.  Guiding flying-spot laser transepithelial phototherapeutic keratectomy with optical coherence tomography.

Authors:  Yan Li; Hideaki Yokogawa; Maolong Tang; Winston Chamberlain; Xinbo Zhang; David Huang
Journal:  J Cataract Refract Surg       Date:  2017-04       Impact factor: 3.351

2.  Quantification of biomechanical properties of human corneal scar using acoustic radiation force optical coherence elastography.

Authors:  Xiao Han; Yubao Zhang; Yirui Zhu; Yanzhi Zhao; Hongwei Yang; Guo Liu; Sizhu Ai; Yidi Wang; Chengfeng Xie; Jiulin Shi; Tianyu Zhang; Guofu Huang; Xingdao He
Journal:  Exp Biol Med (Maywood)       Date:  2021-12-03

3.  Phototherapeutic keratectomy: Indications, methods and decision making.

Authors:  Rashmi Deshmukh; Jagadesh C Reddy; Christopher J Rapuano; Pravin K Vaddavalli
Journal:  Indian J Ophthalmol       Date:  2020-12       Impact factor: 1.848

4.  Optical Coherence Tomography-Guided Femtosecond LASIK in the Setting of Corneal Scarring.

Authors:  Sloan W Rush; Ryan B Rush
Journal:  Clin Ophthalmol       Date:  2021-04-20

5.  Aberrometric, Keratometric, and Visual Outcomes After Trans-Epithelial Topography-Guided Phototherapeutic Keratectomy for the Treatment of Irregular Corneas.

Authors:  Antonio Cano-Ortiz; Pablo Morales; Álvaro Sánchez-Ventosa; Isabel Leiva-Gea; Alberto Membrillo; Vasyl Druchkiv; Timoteo González-Cruces; José-María Sánchez-González; Jaime Beltrán; Alberto Villarrubia
Journal:  Clin Ophthalmol       Date:  2021-09-07

6.  Optical Coherence Tomography-Guided Transepithelial Phototherapeutic Keratectomy for Central Corneal Opacity in the Pediatric Population.

Authors:  Sloan W Rush; Ryan B Rush
Journal:  J Ophthalmol       Date:  2018-12-24       Impact factor: 1.909

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.